In the final segment of our roundtable series, the panelists discuss the treatment of CRPC, focusing on metastatic disease. In the fifth segment of our roundtable series, the treatment of patients with CRPC is discussed. In the fourth part of our series, the panelists discuss PROs and potential patient comorbidities. In the third part of this series, disparities and the optimization of care is discussed, along with the use of ADT and ARPIs. In the second segment of our roundtable series, the panelists discuss their approaches to the use of PSMA PET for patients. In the first part of this series, the panel discusses treatments in the post-salvage setting and review therapeutic options. Watch the "Front-Line Therapy in Papillary Renal Cancer" session from Uromigos Live 2024. View the live recording of the "The Uromigos' Definition of Oligometastatic" session from Uromigos Live 2024. At ESMO Congress 2024, Drs. Petros Grivas, Bernadett Szabados, and Karine Tawagi discuss ctDNA biomarkers. Dr. Oliver Sartor gives an overview of the SPLASH trial on PSMA-targeted therapies for patients with prostate cancer. View the IO Rechallenge panel session from Uromigos Live & Unplugged 2024, recorded live in Nashville. The Radioligands panel at Uromigos Live & Unplugged 2024 explored the role of RLT in prostate cancer treatment. Watch the T Cell Directed Therapy in Prostate Cancer session from Uromigos Live 2024. View the live recording of the "Will New Antibody Drug Conjugates Cure Bladder Cancer?" session from Uromigos Live 2024. Featuring Tom Powles, MD; Petros Grivas, MD; Shilpa Gupta, MD; Kala Sridhar, MD; and Andrea Apolo, MD. Dr. Sonpavde analyzes the efficacy of the SMARCA2 degrader, nivolumab plus gemcitabine and cisplatin, and more. Dr. Guru Sonpavde discusses urothelial carcinoma trials AMBASSADOR, NIAGARA, CM901, and PRT3789. Dr. Gerhardt Attard discusses the benefits of the Decipher score as utilized during the STAMPEDE trial. The Decipher score demonstrated a notable benefit in predicting patient survival rates during the STAMPEDE trial. Dr. Gerhardt Attard provides insight on the STAMPEDE study, along with the Decipher score used during the trial.